December 1, 2016

MV(4;11): A model of human AML (acute myeloid leukemia)

In an effort to more effectively evaluate treatments preclinically, Labcorp offers a human AML model, MV(4;11) (FUW-Luc-mCherry-puro), that has been modified to include both luciferase and mCherry reporter constructs.  Through expression of luciferase, bioluminescent imaging (BLI) can be used to quantitatively measure and track in vivo

May 1, 2017

MM.1S: A model for multiple myeloma

Multiple myeloma is a clonal B cell malignancy characterized by the accumulation of terminally differentiated, antibody-producing plasma cells in the bone marrow. Genetic mutations within the myeloma cells and their interaction with various cytokines and growth factors contribute to the invasiveness of the disease and enhanced drug resistance.

March 1, 2020

Measuring Tumor Antigen-Specific Immunity Through ELISpot and FluoroSpot

While numerous assays are available to measure antigen specificity, many of these have limitations as they necessitate the use of model-specific reagents, genetically engineered animals, or cell subset purification steps. Our Preclinical Oncology offers a simplistic and affordable solution through ELISpot/FluoroSpot analysis.